Triclabendazole
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | ? |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | oxidation to the sulfone and sulfoxide parent compound |
Elimination half-life | 22 - 24 hs |
Excretion | >95% in faeces, 2% in urine, and < 1% in milk |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C14H9Cl3N2OS |
Molar mass | 359.658 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Triclabendazole |
Articles |
---|
Most recent articles on Triclabendazole Most cited articles on Triclabendazole |
Media |
Powerpoint slides on Triclabendazole |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Triclabendazole at Clinical Trials.gov Trial results on Triclabendazole Clinical Trials on Triclabendazole at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Triclabendazole NICE Guidance on Triclabendazole
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Triclabendazole Discussion groups on Triclabendazole Patient Handouts on Triclabendazole Directions to Hospitals Treating Triclabendazole Risk calculators and risk factors for Triclabendazole
|
Healthcare Provider Resources |
Causes & Risk Factors for Triclabendazole |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Triclabendazole (commercial names: veterinary, liquid: Fasinex; human, tablets: Egaten, both manufactured by Novartis) is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group. Benzimidazoles such as triclabendazole are generally accepted to bind to beta-tubulin and prevent the polymerization of the microtubules of which they are part.
Triclabendazole was initially only developed as an oral route drug, and displays high efficacy against both immature and adult liver flukes.
Since late 1990s, triclabendazole became available as a generic drug, as patents expired in many countries. Many products were developed then. Among them, Trivantel 15, a 15% triclabendazole suspension, was launched by Agrovet Market Animal Health in the early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched, also by Agrovet Market Animal Health. The product, Fasiject Plus, a triclabendazole 36% and ivermectin 0.6% solution, is designed to treat infections by Fasciola hepatica (both immature and adult liver flukes), roundworms and ectoparasites, as well.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[1]
References
- ↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Benzimidazoles
- Anthelmintics
- Organochlorides
- Phenol ethers
- Drug